Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247

Stock Information for Satellos Bioscience Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Satellos Bioscience Inc.

Satellos to Present at the 31st Annual Congress of the World Muscle Society
Satellos to Participate in Upcoming Investor Conferences
Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress
Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247
Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
Satellos to Present Clinical Program Updates at ICNMD 2026
Satellos Bioscience Announces Results of Annual Meeting of Shareholders
Satellos to Participate in Upcoming Investor Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.